Focusing on rare kidney diseases with unique collaborative efforts
Explore Fortrea's unique collaborative efforts in researching and addressing rare kidney diseases through advanced methodologies and patient-centric approaches.
SGLT2 inhibitors as renoprotective agents for pediatric patients living with chronic kidney disease
Explore the benefits of SGLT2 inhibitors as renoprotective agents for pediatric patients. Fortrea’s blog provides insights into diabetes medication and renal protection.
Delivering efficient, technology-driven patient safety sollutions
This infosheet explores Fortrea's pharmacovigilance and patient safety solutions.
Serving as an extended safety partner for an emerging biotech's vaccine studies
This case study outlines how Fortrea served as an extended safety partner for an emerging biotech's vaccine studies.
Exceeding challenging milestones through teamwork and innovation
This case study delves into meeting and exceeding trial milestones on very short timelines.
Sharing our best patient-centric practices from extensive experience in Alzheimer’s Disease.
At Fortrea, we’re committed to advancing research in Alzheimer’s Disease (AD) and other dementias. Learn about our best practices and recommendations developed from years of experience advancing these complex studies.
Going beyond the boundaries of a clinical trial: how Dr. Barbara Gillespie is working to address disparities in kidney disease
As part of her commitment to advancing nephrology research, Dr. Gillespie is helping build trust in clinical trials within patient groups. H
Unleashing the power of data sharing to transform the drug development landscape for kidney diseases
In 2016, Barbara Gillespie, MD, FASN, Vice President and Therapeutic Head of Nephrology at Fortrea, joined a workgroup with the Kidney Health Initiative (KHI) and U.S. FDA. T